Mutations in the gene encoding 11S -hydroxysteroid dehydrogenase type 2, HSD11B2 , cause a rare monogenic juvenile hypertensive syndrome called apparent mineralocorticoid excess (AME). In AME, defective 
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Introduction
In mineralocorticoid target organs, the 11 β -hydroxysteroid dehydrogenase (HSD11B) catalyzes the interconversion of the endogenous cortisol and cortisone in humans. Two distinct forms, HSD11B1 and HSD11B2, of HSD11B have been characterized and cloned ( 1 -3) . HSD11B1 is expressed in most tissues. In contrast, HSD11B2 has been identified in a limited range of tissues, such as the distal tubules of the kid-ney (2, 4, 5) . In mineralocorticoid-responsive cells, HSD11B2 converts cortisol to cortisone, which is not a ligand for the mineralocorticoid receptor, permitting aldosterone to occupy the receptor.
Apparent mineralocorticoid excess syndrome (AME) is an autosomal recessive disorder that results in severe low-renin hypertension and other characteristic clinical features (6) (7) (8) . Typical patients present with severe hypertension, hypokalemia, and undetectable aldosterone. Most patients also have low birth weight, polyuria and polydipsia, failure to thrive, and nephrocalcinosis. The syndrome has been associated with sudden fatality. The HSD11B2 deficiency has been demonstrated in patients with AME and explains the pathogenesis of the disease, which results from excess cortisol binding to the mineralocorticoid receptor due to a failure to convert cortisol to cortisone (9) (10) (11) . Over the last two decades, various genetic mutations in the HSD11B2 gene have been reported (12) (13) (14) (15) (16) (17) . In Japanese patients with AME, two missense mutations (S180F, R208H) and a deletion of 3 nucleotides resulting in R337H and delta Y338 have been identified (14, 18) .
In 1998, a mild form of this disease characterized by P227L mutation in the HSD11B2 gene was reported (19) . In contrast to the patients with AME, this patient had low-renin hypertension and hypoaldosteronism but no other phenotypic features that would lead to the diagnosis of AME. Afterwards, it was reported that the defective allele frequency in a cohort of Mennonites was 1.7% (20) . The genetic mutation in the HSD11B2 gene, which results in a mild HSD11B2 deficiency, may represent an important cause of low-renin hypertension, the diagnostic basis of which is mostly unknown. Together, these findings suggest that, because 40% of patients with essential hypertension have low renin, these patients may have a mild form of AME.
In the HSD11B2 gene, the 535G> A polymorphism (synonymous mutation at E178) in exon 3, which can be distinguished by Alu I cleavage and the polymorphic microsatellite marker (21) , have been reported. The minor allele frequency of the 553G> A polymorphism was 0.086 in a healthy Caucasian population and 0.180 in a group of renal transplant patients (n= 61), indicating association of this polymorphism with end-stage renal disease. This polymorphism was not associated with essential hypertension (22) . As for the microsatellite marker, a total of 12 alleles were detected. The urinary ratio of cortisol to cortisone metabolites was higher in subjects homozygous for the A7 microsatellite allele than in the corresponding control subjects. Thus, the association of a polymorphic microsatellite marker of the HSD11B2 gene with reduced HSD11B2 activity suggests that variants of the HSD11B2 gene contribute to enhanced blood pressure response to salt in humans (23) . The study demonstrated that a salt-induced blood pressure increase is associated with impaired HSD11B2 activity, as measured by the urinary excretion ratio of cortisol to cortisone metabolites in young Caucasian salt-sensitive men.
The present study was undertaken 1) to identify the genetic variants in the HSD11B2 gene in Japanese hypertensives, 2) to address whether individuals with heterozygous missense/ frameshift mutations show hypertension or renal impairment, and 3) to explain the genetic contribution to a mild form of hypertension including low-renin hypertension and hypoaldosteronism. We sequenced the promoter and exon regions of HSD11B2 in Japanese hypertensives and genotyped the rare missense/frameshift mutations in the general population. We assessed the role of these genetic variations in hypertension and clarified their contribution to hypertension in Japanese.
Methods

Hypertensive Patients
A total of 953 hypertensive patients (522 men and 431 woman; average age: 65.0±10.5 years) were recruited from the Division of Hypertension and Nephrology at the National Cardiovascular Center as reported previously (24) (25) (26) (27) . Briefly, 92% of study subjects (880 subjects) were diagnosed with essential hypertension, and the rest had secondary hypertension (Table 1) . Hypertension was defined as systolic blood pressure (SBP) of ≥ 140 mmHg, and/or diastolic blood pressure (DBP) of ≥ 90 mmHg, or current use of antihypertensive medication. Hyperlipidemia was defined by total cholesterol ≥ 220 mg/dl or current use of antihyperlipidemia medication.
Diabetes mellitus was defined by fasting plasma glucose ≥ 126 mg/dl or HbA1c ≥ 6.5% or current use of anti-diabetic medication. Study subjects had routine laboratory tests including electrolytes, renal function, blood glucose, HbA1c, plasma renin activity and plasma aldosterone concentration. 
Sequencing of the HSD11B2 Gene
We sequenced all exons and the promoter region of HSD11B2 in 953 Japanese hypertensive patients. Blood samples were obtained from hypertensive patients and genomic DNA was isolated from peripheral blood leukocytes. All exons with their flanking sequences and about 1.6 kb of the upstream region were directly sequenced with an ABI PRISM 3700 DNA analyzer (Applied Biosystems, Foster City, USA) using seven sets of primers, as described previously (28) . Information on the primers and polymerase chain reaction (PCR) conditions is available on request. The obtained sequences were examined for the presence of variations using Sequencher software (Gene Codes Corporation, Ann Arbor, USA), followed by visual inspection. The A of the ATG of the initiator Met codon is denoted as nucleotide +1. The nucleotide sequence (GenBank Accession ID: NT_010498) was used as a reference sequence.
General Population (the Suita Study)
The sample selection and study design of the Suita Study have been described previously (29, 30) . Briefly, the subjects visited the National Cardiovascular Center every 2 years for general health checkups. In addition to performing a routine blood examination that included lipid profiles, glucose levels, blood pressure, anthropometric measurements, a physician or nurse administered questionnaires covering personal history of cardiovascular diseases, including angina pectoris, myocardial infarction, and/or stroke. Blood pressure was measured after at least 10 min of rest in a sitting position. SBP and DBP were means of two measurements performed by welltrained doctors using a mercury sphygmomanometer (with a 3-min interval). The subjects were classified as current drinkers if they drank at least 30 ml ethanol per day, nondrinkers if they had never drunk, and past drinkers if they previously had drunk above 30 ml ethanol per day.
Genotyping of Genetic Variations in the General Population
Genotyping was attempted for six rare missense/frameshift mutations using the TaqMan-PCR method (31) . The sequences of PCR primers and probes for the TaqMan-PCR method are available on request. Genotyping for two of the six rare mutations-4582C> T (encoded T156I) and 4884Gdel (a frameshift mutation)-failed. Thus, four genetic variations were successfully genotyped in 3,655 participants (1,709 men and 1,946 women) of the large cohort known as the Suita Study. All of the participants for genetic analysis in the present study gave their written informed consent. All clinical data and sequencing and genotyping results were anonymous. The study protocol was approved by the Ethical Review Committee of the National Cardiovascular Center. 
Results
Identification of Genetic Variations in HSD11B2 in a Japanese Hypertensive Population
We sequenced the promoter and exon regions of HSD11B2 in 953 hypertensives. As a result, we did not identify the reported common genetic variations in Caucasians and causative genetic variations of AME in the HSD11B2 gene. Instead, we identified five novel missense mutations and one frameshift mutation in HSD11B2 (Fig. 1 , Table 2 ). Five patients had a C-to-T substitution at nucleotide 40 in exon 1, which led to an amino acid substitution from L to F at position 14 (L14F). One patient had a G-to-A substitution at nucleotide 221 in exon 1, resulting in an amino acid substitution from R to H at position 74 (R74H). Three patients had a G-to-A substitution at nucleotide 4554 in exon 2, leading to an amino acid substitution from R to H at position 147 (R147H). One patient had a C-to-T substitution at nucleotide 4582 in exon 2, leading to an amino acid substitution from T to I at position 156 (T156I). One patient had a G-to-A substitution at nucleotide 5541 in exon 5, resulting in an amino acid substitution from R to H at position 335 (R335H). We also found one patient with a frameshift mutation that resulted from a guanine deletion at position 4884 in exon 3 (4884Gdel). These missense/frameshift mutations were all found in the heterozygous form. We also identified five synonymous polymorphisms, which encoded for L14 (42C> A in exon 1) with a minor allele frequency of 0.001%, L28 (82C> T in exon 1) with a minor allele frequency of 0.001%, P227 (5017G > A in exon 4) with a minor allele frequency of 0.003%, Y295 (5422C > T in exon 5) with a minor allele frequency of 0.0003% and Q387 (5698G> A in exon 5) with a minor allele frequency of 0.0003%. Fourteen additional genetic variations in the promoter, intronic, and 3′-untranslated regions were also identified. All of the genetic variations were rare, with minor allele frequencies less than 0.005 (Table 2) . The A of the ATG of the initiator Met codon is denoted nucleotide +1, as recommended by the Nomenclature Working Group ( 37 ). The nucleotide sequence (GenBank Accession ID: NT_010498) was used as a reference sequence. UTR, untranslated region; freq., frequency. Missense mutations were genotyped for general population except two mutations of which genotypes were not determined.
Characteristics of Patients with Rare Missense/ Frameshift Mutations in the Hypertensive Population
The characteristics of the 12 hypertensive patients who had missense/frameshift mutations (L14F, n = 5; R74H, n = 1; R147H, n = 3; T156I, n = 1; 4884Gdel, n = 1; R335H; n = 1) are shown in Table 3 . Five patients out of the twelve had renal impairment including protein urea. Two (cases 1 and 2) of five patients with the L14F mutation had chronic renal failure (CRF) and chronic glomerulonephritis (CGN), and one (case 8) of three patients with the R147H mutation also had CRF. A patient with 4884Gdel (case 11) was diagnosed with renovascular hypertension caused by atherosclerosis with type 2 diabetes, hyperlipidemia and obesity (body mass index [BMI]: 29.97 kg/m 2 ). This patient was 75 years old, female, and had never smoked or drunk alcohol. This patient had microalbuminurea (urinary albumin excretion: 30.8 mg/g creatinine) without renal dysfunction (creatinine clearance: 112.5 ml/ min) or cardiac hypertrophy (left ventricular mass index: 126.4 g/m 2 ). The average onset age of hypertension of the 12 patients with these missense mutations was 50.5 years. A patient with the R335H mutation (case 12) showed hypertension at her age of 26. Serum sodium levels of all patients were within normal range. There were no patients with hypokalemia as seen in AME. 
Characteristics of Individuals with Rare Missense/Frameshift Mutations in the General Population
The characteristics of the 3,655 subjects comprising the Japanese general population group (1,709 men, 1,946 women) are summarized in Table 4 . Age, SBP, DBP, BMI, percentage of current smokers, percentage of current drinkers, and prevalence of hypertension and diabetes mellitus were significantly higher in men than in women. Total cholesterol, high-density lipoprotein (HDL)-cholesterol, and percentage of hyperlipidemia were significantly higher in women than in men. In this population, 1,480 subjects were diagnosed with hypertension.
We successfully genotyped four genetic variations in the general population, which had a sample size of 3,655 individuals (2,175 normotensives and 1,480 hypertensives), but the genotyping failed for two of the genetic variations, T156I and 4884Gdel. In the general population, a missense mutation, R335H, was not present. The remaining three mutations, L14F, R74H, and R147H, were found in both hypertensive and normotensive subjects (Table 5) . We identified 14 individuals with the L14F mutation. Six individuals with the L14F mutation had hypertension and eight were normotensive. We identified 20 individuals with the R74H mutation. Among them, eight showed hypertension and 12 were normotensive. We identified 8 individuals with the R147H mutation. Among them, three showed hypertension and five were normotensive. There were no statistically significant differences in any clinical characteristics between the subjects with the three missense mutations of HSD11B2 and the subjects in the general population (Table 5) .
Comparison of Missense/Frameshift Mutations in HSD11B2 between Normotensives and Combined Hypertensives
As seen in Table 6 , there was no difference in the prevalence of missense/frameshift mutations of HSD11B2 between the combined subjects with hypertension and the normotensives.
Discussion
A missense mutation, P227L, in HSD11B2 was previously identified in a patient with mild low-renin hypertension ( 32 ) . This patient did not demonstrate the typical features of AME. The authors suggested that patients with mild low-renin hypertension may carry the mutations in the HSD11B2 gene. In our study, we did not identify the P227L mutation in 953 Japanese hypertensives.
Genetic analyses of HSD11B2 have been reported in two Japanese AME probands ( 14 , 18 ) . In one family, the proband had a compound heterozygous mutation with a missense mutation, R208H, and a deletion of 3 nucleotides in codons 337-338 resulting in a substitution of Arg337 to His and a deletion of Tyr338 (CGCTAT to CAT: R337H and delta Y338) ( 18 ) . Their family members, a father, mother, and elderly sister, who carried the heterozygous mutation were all normotensive and normokalemic, and had normal ratios of urinary [THF plus aTHF]/THE (THF, tetrahydrocortisol; aTHF, allotetrahydrocortisol; THE, tetrahydrocortisone). Another Japanese patient with AME had the homozygous missense mutation, S180F. The enzymatic activity of this mutant was 1.8% compared with the wild-type enzyme when cortisol was used as the substrate and 5.7% when corticosterone was used as the substrate ( 14 ) . Figure 1 summarizes the reported polymorphisms in HSD11B2. In our study, none of the three causative genetic defects was identified, indicating that those mutations were not accumulated in the Japanese population.
We identified five novel missense mutations and one frameshift mutation in HSD11B2 (Fig. 1, Table 2 ). As shown in Fig. 2A , five of the missense mutations occurred in residues that were highly conserved among the three different species, indicating that these mutations may result in functional changes in HSD11B2. However, neither hypertensive patients nor general subjects with these novel missense mutations showed any distinctive clinical characteristics during their health-check-ups.
We identified one hypertensive patient having renal artery stenosis with a frameshift mutation (4884Gdel) in HSD11B2. This deletion caused the frameshift at S219 with a premature stop codon at position 270 (Fig. 2B) . A recent report indicated that the heterozygous carriers with the defective allele of the HSD11B2 gene showed essential hypertension (16) . It is evident that this frameshift mutation results in the dysfunction of HSD11B2. The allele frequency of this mutation was very low (0.052%, 1 allele/1,906 alleles) in the Japanese hypertensive population. However, it is worth noting that this defective allele might be prevalent in other ethnic populations, because the frequency of some genetic mutations varies with ethnicity. Recently, rare genetic mutations collectively contributing to a quantitative trait variation, such as plasma levels of HDL-cholesterol, have been reported (33) . We have performed large-scale sequence analyses of five hypertension candidate genes, WNK4, SCNN1B, SCNN1G, NR3C2 and RGS2, to evaluate this hypothesis and found that a low but significant percentage of the hypertensive subjects had missense/frameshift mutations (24) (25) (26) 34) . Collectively, these rare mutations may make an at least partial contribution to hypertension.
The deduced NAD-binding sites reside in the conserved region from T82 to A111 (2) , and the deduced catalytic site resides in the conserved region from Y232 to K236 (35) . So far, more than ten genetic defects in patients with AME, most of whom had a severe deficiency of enzymatic activity confirmed by the expression analysis, have been reported and none of them overlap with the five missense mutations identified in the present study. Therefore, the effects on the HSD11B2 enzymatic activity of the mutations are not clear. In the future, an in vitro expression study should be performed to evaluate the activity of mutants and the ratios of urinary cortisol to cortisone metabolites in carriers of the mutations.
In the Caucasian population, a mutation at E178 that is synonymous with 553G> A which can be distinguished by Alu I restriction enzyme digestion, has been identified with a prevalence of 8.6% in the control subjects (21, 23) . This polymorphism was associated with end-stage renal disease but not with essential hypertension. We did not identify this polymor- Values were expressed as mean±SD. Hypertension: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or antihypertensive medication; hyperlipidemia: total cholesterol ≥220 mg/dl or antihyperlipidemia medication; diabetes: fasting plasma glucose ≥126 mg/dl or non-fasting plasma glucose ≥200 mg/dl or HbA1c ≥6.5% or antidiabetic medication. M, male; F, female; HDL, high-density lipoprotein; FBS, fasting blood sugar. phism in our Japanese population. In the Caucasian population, an intensive genetic study on the HSD11B2 gene using 587 subjects, including 260 patients with end-stage renal disease, has been conducted, in which one missense mutation, L148V, and three synonymous mutations, T156, E178, and D388, were identified by the combination of single strand conformational polymorphism analysis and DNA sequencing (36) . The results showed that allele frequencies did not differ significantly between control subjects and end-stage renal disease patients or between patients with hypertension and patients with end-stage renal disease. We did not identify these mutations in our Japanese population. Our results support their findings that the mutations in the HSD11B2 gene do not affect hypertension.
In summary, we suggest that rare mutations in HSD11B2, L14F, R74H, R147H, T156I, R335H, and 4884Gdel may not collectively contribute to the pathogenesis of hypertension, although it was not clear whether abnormalities of electrolytes, renin activity, or aldosterone concentration were present, since our hypertensive patients with these missense/ frameshift mutations were taking antihypertensive drugs. Further functional analyses of HSD11B2 mutants are necessary to clarify the functional defects caused by these genetic variations in Japanese. 
